1. Home
  2. TMQ vs OVID Comparison

TMQ vs OVID Comparison

Compare TMQ & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

HOLD

Current Price

$2.98

Market Cap

579.8M

ML Signal

HOLD

Logo Ovid Therapeutics Inc.

OVID

Ovid Therapeutics Inc.

HOLD

Current Price

$2.31

Market Cap

522.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMQ
OVID
Founded
2004
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
579.8M
522.6M
IPO Year
2012
2017

Fundamental Metrics

Financial Performance
Metric
TMQ
OVID
Price
$2.98
$2.31
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$4.60
AVG Volume (30 Days)
1.8M
3.4M
Earning Date
04-02-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.90
EPS
N/A
N/A
Revenue
N/A
$7,252,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1181.27
52 Week Low
$1.43
$0.48
52 Week High
$11.29
$3.11

Technical Indicators

Market Signals
Indicator
TMQ
OVID
Relative Strength Index (RSI) 32.39 41.05
Support Level N/A $2.23
Resistance Level $4.98 $2.38
Average True Range (ATR) 0.19 0.17
MACD -0.01 -0.03
Stochastic Oscillator 22.22 0.99

Price Performance

Historical Comparison
TMQ
OVID

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About OVID Ovid Therapeutics Inc.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Share on Social Networks: